Meeting
2017 ASCO Annual Meeting
Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor.
Authors
Kimberly Mayumi Komatsubara
Columbia University Medical Center, New York, NY
Kimberly Mayumi Komatsubara , Alexander Noor Shoushtari , Sapna Pradyuman Patel , Parisa Momtaz , Shahnaz Singh-Kandah , Amanda Carter , Suzanne Cain , Lauren Taiclet , Sarah DeNoble , Tiffany Negri , Danielle Lacey , Grazia Ambrosini , Shing Mirn Lee , Gary K. Schwartz , Richard D. Carvajal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02768766
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS9597)
DOI
10.1200/JCO.2017.35.15_suppl.TPS9597
Abstract #
TPS9597
Poster Bd #
202a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.
First Author: Elizabeth Iannotti Buchbinder
Poster
2017 ASCO Annual Meeting
SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer.
First Author: Richard D. Kim
Poster
2016 ASCO Annual Meeting
Second-line chemotherapy efficacy in patients with previously treated advanced thymic carcinoma: A retrospective analysis of 192 patients from NEJ023 Study.
First Author: Shunichiro Iwasawa
Poster
2013 ASCO Annual Meeting
Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib.
First Author: Andrew H. Ko